N/A N=21 Hearing Aid Processing and Working Memory in Realistic Spatial Conditions
Hearing Loss, Sensorineural
Primary: Speech Intelligibility (Percent Correct Scores) — 0.55; 0.59; 0.70; 0.80 percentage of words correct — p=0.5291
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=43 Fit 24 Technology Intervention YOUTH
Diabetes Mellitus, Type 2
Primary: Number Participants Recruited — 21; 22 Participants
N/A N=16 MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer
Breast Cancer
Primary: Reproducibility of the MRI Vascular Permeability (Kep)
N/A N=319 Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope
Biliary Disease · Pancreatic Disease · Choledocholithiasis
Primary: Number of Participants With Procedure-related Adverse Events — 8; 9 Participants — p=0.8
Phase 1 N=6 A Safety Study of the Auditory Brainstem Implant for Pediatric Profoundly Deaf Patients
Profound Bilateral Deafness Due to · Bilateral Cochlear Aplasia · Bilateral Cochlear Nerve Deficiency
Primary: Primary Endpoint — 6 Participants
N/A N=2,150 Integrated Care Delivery of HIV Prevention and Treatment in AGYW in Zambia
HIV
Primary: HIV Testing — 33; 52; 139 Participants
Phase 2 N=32 Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
Chronic Lymphocytic Leukemia
Primary: Safety, Tolerability and Dose Limiting Toxicity (DLT) of Ibrutinib in Combination With Obinutuzumab — 32 Participants
N/A N=631 Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)
Cancer Treated With Immune-checkpoint Inhibitors
Primary: Correlation Between Time to Next Treatment or Death (TNT-D) and Overall Survival (OS) — 0.63; 0.66 correlation coefficient
Phase 2 N=53 Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
Relapsed Diffuse Large B-cell Lymphoma · Refractory Diffuse Large B-cell Lymphoma
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 24; 28; 9; 8 Participants
Phase 1 N=11 Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Alzheimer Disease
Alzheimer Disease
Primary: Change in WAB-AQ Score — -1.7; -.1 score on a scale — p=<.05
N/A N=147 Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System
Vascular Closure
Primary: Freedom From Major Complications — 83 Participants
Phase 3 N=4,328 A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
SARS-CoV-2
Primary: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 586; 585; 627; 42 Participants
N/A N=32 The Pediatric Artificial Pancreas Automated Initialization Trial
Type 1 Diabetes
Primary: Safety Endpoint (Tested for Non-inferiority Compared to Baseline) CGM Measured (a) — 0.3; 0.3 percentage of time
N/A N=37 Clinical Evaluation of Proclear Toric and Biofinity Toric
Astigmatism
Primary: Overall Fit Acceptance — 3.5; 3.8 Units on Scale
N/A N=240 Prevention of OUD: The HOME Project (Housing, Opportunities, Motivation and Engagement)
Substance Use
Primary: Frequency (% Days) of Opioid Use in Prior 3 Months — 0; 0 % days opioid use